← All trials
NCT04419402
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 1, 2020
- Primary completion
- Jun 1, 2022
- Completion date
- Jun 1, 2023
- First posted
- Jun 5, 2020
- Last posted
- Jun 5, 2020
- Enrollment
- 160
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Australian and New Zealand Urogenital and Prostate Cancer Trials GroupLead sponsor
- AstellasCollaborator
- University of New South WalesStudy chair
- EndocyteCollaborator
- Prostate Cancer Research AllianceCollaborator
- Australian Nuclear Science and Technology OrganisationCollaborator
- Government of AustraliaCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.